Generation Bio (GBIO) director reports option cash-out and cancellations in XOMA Royalty merger
Rhea-AI Filing Summary
Generation Bio Co. completed a merger in which XRA 7 Corp. was merged into the company, effective February 9, 2026. After this transaction, Generation Bio continues as the surviving corporation and a wholly owned subsidiary of XOMA Royalty Corporation.
In connection with the merger, director Jonas Jeffrey M reported the disposition of several stock options. Under the Merger Agreement, each outstanding, unexercised option with an exercise price below the defined cash amount of $4.2913 became fully vested and was cancelled in exchange for a cash payment based on that spread. Options with exercise prices at or above $4.2913 were automatically cancelled for no consideration, leaving him with no remaining options of these series.
Positive
- None.
Negative
- None.
Insights
Merger converts in-the-money director options to cash and cancels the rest.
The Merger Agreement between Generation Bio Co. and XOMA Royalty Corporation triggers standard change-of-control mechanics for director stock options. As of February 9, 2026, Generation Bio became a wholly owned subsidiary of XOMA Royalty Corporation.
Each outstanding stock option with an exercise price below the defined cash amount of $4.2913 was fully vested, cancelled, and converted into a cash right based on the spread versus that cash amount. Options with exercise prices at or above $4.2913 were cancelled with no payment.
For director Jonas Jeffrey M, this means his reported stock option positions were eliminated: one tranche generated a cash entitlement under the formula, while multiple higher-strike grants were written off. Subsequent company disclosures may provide additional detail on overall post‑merger capital structure.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (right to buy) | 3,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 4,246 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 5,200 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 1,500 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 1,920 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 2,500 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 6,000 | $0.00 | -- |
Footnotes (1)
- Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was less than $4.2913 (the "Cash Amount") (each such option, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time. Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
